Mapping the polar metabolome in Huh-7 liver cancer cells reveal the role of atorvastatin in enhancing chemotherapeutic efficacy of doxorubicin
Journal of Pharmaceutical and Biomedical Analysis · 2025
DOI: 10.1016/j.jpba.2025.117012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2025. Verfasst von Maria Kopsida und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Cell Biology, Uppsala University, Box 571, Uppsala SE-751 23, Sweden. Hauptthemen laut MEDLINE: Atorvastatin, Doxorubicin, Liver Neoplasms, Metabolome. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Society for Medical Research, Swedish Research Council, Goran Gustafsson's Foundations.
Abstract (Originalsprache)
Hepatocellular carcinoma is an aggressive cancer characterized by metabolic reprogramming in lipid-, nucleotide and amino acid metabolism/catabolism and oxidative stress management. This in vitro study investigates the potential cytotoxic and metabolic effects of the novel combination of doxorubicin and atorvastatin, a cholesterol-lowering drug, in the well-characterized Huh-7 cell line. The cytotoxicity of statins and fibrates was assessed through dose-response curves and the half-maximal inhibitory concentration (IC50) for each treatment, both individually and in combination. Synergism was determined using the Chou-Talalay method. Among the tested agents, atorvastatin exhibited the most potent cytotoxicity, with an IC50 of 70.45 µM. When combined with doxorubicin, the IC50 of doxorubicin decreased significantly from 165.25 µM to 26.85 µM, indicating a synergistic effect. Metabolic profiling revealed distinct changes in lipid metabolism, fatty acid oxidation and the carnitine shuttle system, specifically within the combination treatment. The combination treatment also seems to affect oxidative stress management via the urea cycle, polyamine biosynthesis, and catabolism of nucleotides and amino acids. By limiting energy production, while simultaneously disrupting oxidative stress management, this therapy creates a plausible metabolic bottleneck, which may impair cancer cell adaptation to stress and growth. These findings suggest that combining atorvastatin with doxorubicin might enhance treatment efficacy and/or reduce resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Cell Biology, Uppsala University, Box 571, Uppsala SE-751 23, Sweden.
- European Livestock Diagnostic Center BV, PO Box 369, Kerkrade 6460AJ, the Netherlands.
- Department of Pharmaceutical Biosciences; Research; Translational Drug Discovery and Development, Box 591, Uppsala SE-751 24, Sweden.
- Department of Medicinal Chemistry, Uppsala University, Box 574, Uppsala SE-751 23, Sweden.
- Department of Medicinal Chemistry, Uppsala University, Box 574, Uppsala SE-751 23, Sweden. Electronic address: mikael.engskog@ilk.uu.se.
Förderung
- Swedish Society for Medical Research
- Swedish Research Council
- Goran Gustafsson's Foundations
- Swedish Cancer Foundation
- Swedish Cancer Society
Zitieren
APA
Kopsida, M., Regtop, L., Lennernäs, H., Hedeland, M., Heindryckx, F., & Engskog, M. K. R. (2025). Mapping the polar metabolome in Huh-7 liver cancer cells reveal the role of atorvastatin in enhancing chemotherapeutic efficacy of doxorubicin. Journal of Pharmaceutical and Biomedical Analysis. https://doi.org/10.1016/j.jpba.2025.117012
Vancouver
Kopsida M, Regtop L, Lennernäs H, Hedeland M, Heindryckx F, Engskog MKR. Mapping the polar metabolome in Huh-7 liver cancer cells reveal the role of atorvastatin in enhancing chemotherapeutic efficacy of doxorubicin. Journal of Pharmaceutical and Biomedical Analysis. 2025. doi:10.1016/j.jpba.2025.117012
BibTeX
@article{Kopsida2025,
author = {Kopsida, Maria and Regtop, Lotta and Lennernäs, Hans and Hedeland, Mikael and Heindryckx, Femke and Engskog, Mikael K R},
title = {Mapping the polar metabolome in Huh-7 liver cancer cells reveal the role of atorvastatin in enhancing chemotherapeutic efficacy of doxorubicin},
journal = {Journal of Pharmaceutical and Biomedical Analysis},
year = {2025},
doi = {10.1016/j.jpba.2025.117012}
}
EUVIMED